Blueprint Medicines Reports Third Quarter 2017 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Blueprint Medicines Reports Third Quarter 2017 Financial Results

Blueprint Medicines (BPMC) PT Raised to $70 at Wedbush

November 1, 2017 7:17 AM EDT

Wedbush analyst David Nierengarten raised his price target on Blueprint Medicines (NASDAQ: BPMC) to $70.00 (from $66.00) while maintaining a Outperform rating after the company reported enrollment progress across a number of studies of their wholly-owned kinase assets, and reiterated timeline for future trial... More